Author:
Sarduy M R, ,García I,Coca M A,Perera A,Torres L A,Valenzuela C M,Baladrón I,Solares M,Reyes V,Hernández I,Perera Y,Martínez Y M,Molina L,González Y M,Ancízar J A,Prats A,González L,Casacó C A,Acevedo B E,López-Saura P A,Alonso D F,Gómez R,Perea-Rodríguez S E
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Ahmad KA, Wang G, Slaton J, Ungera G, Ahmed K (2005) Targeting CK2 for cancer therapy. Anticancer Drugs 16 (10): 1037–1043.
2. FIGO. Staging classification and clinical practice guidelines of gynecologic cancer Benedet JL, Hacker NF, Ngan HY (2003). Committee on Gynecologic Oncology, IGCS Guidelines Committee 2nd edn pp 36–40.
http://www.figo.org/publications
.
3. Common Terminology Criteria for Adverse Events (CTCAE) (2010) Version 4.0, Published: May 28, 2009 (v4.03: June 14, 2010), DCTD, NCI, NIH, DHHS.
http://ctep.cancer.gov
.
4. Carter RE, Woolson RF (2004) Statistical design considerations for pilot studies transitioning therapies from the bench to the bedside. J Transl Med 2 (1): 37–39.
5. Duncan JS, Litchfield DW (2008) Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 1784 (1): 33–47.
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献